Boehringer Ingelheim Pharma GmbH & Co. KG

At Boehringer Ingelheim Pharma GmbH & Co. KG in Biberach An Der Riss, much of the clinical trial activity centers on healthy volunteer studies designed to understand how new medicines behave in the body and how they are tolerated. The work spans pharmacokinetic research and early treatment assessment, helping support the development of future therapies.

• Studies in healthy adults to evaluate how medicines are absorbed, distributed, and processed in the body
• Research on food effects and tablet or formulation comparisons to improve how treatments are taken
• Trials assessing whether one medicine changes the blood levels of another, supporting safe use with other therapies

These studies focus on building a clearer picture of drug behavior, tolerability, and practical use, which can guide the development of more effective and convenient treatments.

A major theme in the site’s research portfolio is pharmacokinetic trial work, with repeated evaluation of how investigational medicines and approved drugs interact in the body. These studies are important for understanding exposure, compatibility, and how dosing may be influenced by food or other treatments.

• Testing how food affects medicine absorption and overall blood levels
• Comparing different formulations, tablets, or delivery approaches for the same compound
• Examining potential interactions with established medicines such as metformin, dabigatran, and rosuvastatin

This research supports safer and more predictable use of new therapies by clarifying how they behave under real-world conditions and alongside other commonly used medicines.

Although the therapeutic focus is broad and not limited to a single disease area, the site contributes to development programs involving several investigational compounds aimed at advancing treatment options. The studies are centered on testing new therapies, refining formulations, and evaluating how different products perform in healthy participants.

• Development studies involving compounds such as nerandomilast, zongertinib, survodutide, and vicadrostat
• Research on tolerability and exposure to help guide further clinical development
• Evaluation of product design and administration options to improve future patient use

The overall research landscape reflects a strong emphasis on clinical development, with studies designed to support the safe and effective progression of new medicines from early testing toward broader clinical use.